Du Jun, Xu Ren
Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Int J Mol Sci. 2012 Nov 26;13(12):15755-66. doi: 10.3390/ijms131215755.
The function of the nuclear receptor (NR) in breast cancer progression has been investigated for decades. The majority of the nuclear receptors have well characterized natural ligands, but a few of them are orphan receptors for which no ligand has been identified. RORα, one member of the retinoid orphan nuclear receptor (ROR) subfamily of orphan receptors, regulates various cellular and pathological activities. RORα is commonly down-regulated and/or hypoactivated in breast cancer compared to normal mammary tissue. Expression of RORα suppresses malignant phenotypes in breast cancer cells, in vitro and in vivo. Activity of RORα can be categorized into the canonical and non-canonical nuclear receptor pathways, which in turn regulate various breast cancer cellular function, including cell proliferation, apoptosis and invasion. This information suggests that RORα is a potent tumor suppressor and a potential therapeutic target for breast cancer.
几十年来,人们一直在研究核受体(NR)在乳腺癌进展中的作用。大多数核受体具有特征明确的天然配体,但其中有少数是尚未鉴定出配体的孤儿受体。视黄酸孤儿核受体(ROR)亚家族成员之一的RORα,可调节多种细胞和病理活动。与正常乳腺组织相比,RORα在乳腺癌中通常下调和/或低激活。RORα的表达在体外和体内均可抑制乳腺癌细胞的恶性表型。RORα的活性可分为经典和非经典核受体途径,进而调节多种乳腺癌细胞功能,包括细胞增殖、凋亡和侵袭。这些信息表明,RORα是一种有效的肿瘤抑制因子,也是乳腺癌潜在的治疗靶点。